| Name | MG-132 |
| Description | MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis. |
| In vitro | METHODS: Human cervical cancer cells HeLa were treated with MG-132 (0.5-30 μM) for 24 h, and cell growth inhibition was detected by MTT.
RESULTS: MG-132 dose-dependently inhibited HeLa cell growth with an IC50 of approximately 5 μM. [1]
METHODS: Human mesothelioma cells NCI-H2452 were treated with MG-132 (0.25-2 μM) for 36 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: MG-132 treatment induces cleavage of caspases 3 and 7, Bid, and PARP in NCI-H2452 cells. MG-132 induces a caspase-dependent apoptosis. [2]
METHODS: Human melanoma cells MeWo were treated with MG-132 (0.01-1 μM) for 24 h, and the cell cycle profiles were analyzed by Flow Cytometry.
RESULTS: MG-132 induces cell cycle arrest at G2 phase in MeWo cells. [3] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, MG-132 (1 mg/kg) was injected intravenously into C.B-17/lcr-scid/scidJcl mice harboring the human cervical cancer tumors HeLa, CaSki, or C33A twice a week for 4 weeks.
RESULTS: MG-132 significantly inhibited the growth of human cervical cancer tumors, indicating antitumor activity in vivo. [4]
METHODS: To investigate the effects of long-term treatment with MG-132 on cardiac hypertrophy and its associated molecular mechanisms, MG-132 (0.1 mg/kg) was injected intraperitoneally into rats with an abdominal aortic band (AAB) once daily for 8 weeks.
RESULTS: MG-132 treatment significantly attenuated left ventricular myocyte area, left ventricular weight/body weight, and lung weight/body weight ratios, decreased left ventricular diastolic diameter and wall thickness, and increased the shortening fraction in AAB rats. MG-132 treatment significantly reversed the elevated levels of ERK1/2 and JNK1 phosphorylation in AAB rats. [5] |
| Storage | Store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : Insoluble
Ethanol : 47.5 mg/mL (99.87 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9 mg/mL (18.92 mM), Suspension.
DMSO : 240 mg/mL (504.6 mM), Sonication is recommended.
|
| Keywords | proteolytic | Proteasome | peptide | MG-132 | MG 132 | Inhibitor | inhibit | complex | calpain | Autophagy | Apoptosis | aldehyde | 26S | 20S proteasome |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Ubiquitination Compound Library | HIF-1 Signaling Pathway Compound Library | Protease Inhibitor Library | Autophagy Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
